论文部分内容阅读
目的观察奥沙利铂联合替吉奥或替加氟治疗中晚期胃癌的远期临床疗效。方法将50例中晚期胃癌患者随机分为试验组25例和对照组25例。试验组患者给予奥沙利铂130 mg·m~(-2)加入5%葡萄糖注射液500 m L,静脉滴注90 min,第1天;替吉奥40~60 mg·m~(-2),每天2次,第1~14天,休息7 d,21 d为一个周期。对照组患者给予奥沙利铂130 mg·m~(-2)加入5%葡萄糖注射液500 m L,静脉滴注90 min,第1天;替加氟1 g,第1~5天,缓慢静脉注射。有效者给予4个以上周期化疗,直至出现不可耐受毒性。每位患者至少给予2个周期化疗。比较2组患者的近期疗效、远期生存率和药物不良反应发生情况。结果试验组和对照组患者得临床治疗有效率分别为92.0%,64.0%,组间比较差异有统计学意义(P<0.05)。试验组患者短期治疗效果显著优于对照组患者,差异有统计学意义(P<0.05)。试验组的药物不良反应发生率为28%,显著低于对照组患者的96%,差异有统计学意义(P<0.05)。结论奥沙利铂联合替吉奥治疗中晚期胃癌的临床疗效显著优于奥沙利铂联合替加氟,且前者药物不良反应的发生率也显著低于后者。
Objective To observe the long-term clinical efficacy of oxaliplatin in combination with tegaserod or tegafur in the treatment of advanced gastric cancer. Methods Fifty patients with advanced gastric cancer were randomly divided into experimental group (25 cases) and control group (25 cases). Patients in the test group were given oxaliplatin 130 mg · m -2 by adding 500 mL of 5% glucose injection for 90 min on the first day; 40-60 mg · m -2 ), 2 times a day, 1 to 14 days, rest for 7 days and 21 days for one cycle. Control group patients were given oxaliplatin 130 mg · m -2 added 5% glucose injection 500 m L, intravenous infusion of 90 min on the first day; tegafur 1 g, the first 5 days, slow Intravenous injection. Effectively given more than 4 cycles of chemotherapy until intolerable toxicity. Each patient is given at least 2 cycles of chemotherapy. Short-term efficacy, long-term survival and adverse drug reactions were compared between the two groups. Results The effective rates of clinical treatment in trial group and control group were 92.0% and 64.0%, respectively, with significant difference between the two groups (P <0.05). Short-term treatment of patients in the experimental group was significantly better than the control group, the difference was statistically significant (P <0.05). The adverse drug reaction rate in the experimental group was 28%, which was significantly lower than that in the control group (96%) (P <0.05). Conclusion The clinical efficacy of oxaliplatin combined with tirofiban in the treatment of advanced gastric cancer is significantly better than oxaliplatin combined with tegafur, and the incidence of adverse drug reactions in the former is also significantly lower than the latter.